<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: A large proportion of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients does not benefit from the use of anti-epidermal growth factor receptor (EGFR) treatment although in the absence of a mutation of the K-<z:mp ids='MP_0011356'>RAS</z:mp> gene </plain></SENT>
<SENT sid="1" pm="."><plain>Preliminary observations suggested that HER-3, insulin-like growth factor-1 (IGF-1), nuclear factor-kB (NF-kB) and EGFR gene copy number (GCN) might identify patients not likely to benefit from anti-EGFR therapy </plain></SENT>
<SENT sid="2" pm="."><plain>We tested the interaction between HER-3, IGF-1, NF-kB, EGFR GCN and K-<z:mp ids='MP_0011356'>RAS</z:mp> mutational analysis to verify the relative ability of these variables to identify a subgroup of patients more likely to benefit from EGFR-targeted treatment among those harbouring a K-<z:mp ids='MP_0011356'>RAS</z:mp> <z:mp ids='MP_0002169'>wild-type</z:mp> status </plain></SENT>
<SENT sid="3" pm="."><plain>PATIENTS AND METHODS: We retrospectively collected <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> from 168 patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> treated with irinotecan-cetuximab </plain></SENT>
<SENT sid="4" pm="."><plain>K-<z:mp ids='MP_0011356'>RAS</z:mp> was assessed with direct sequencing, EGFR amplification was assessed by chromogenic in situ hybridisation (CISH) and HER-3, IGF-1 and NF-kB were assessed by immunohistochemistry </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: In patients with K-<z:mp ids='MP_0011356'>RAS</z:mp> <z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e>, the following molecular factors resulted independently associated with response rate: HER-3 [odds ratio (OR)=4.6, 95% confidence interval (CI) 1.8-13.6, P=0.02], IGF-1 (OR=4.2, 95% CI 2-10.2, P=0.003) and EGFR GCN (OR=4.1, 95% CI 1.9-26.2, P=0.04) </plain></SENT>
<SENT sid="6" pm="."><plain>These factors also independently correlated with overall survival as follows: HER-3 [hazard ratio (HR)=0.4, 95% CI 0.28-0.85, P=0.008], IGF-1 (HR=0.47, 95% CI 0.24-0.76, P&lt;0.0001) and EGFR GCN (HR=0.59, 95% CI 0.22-0.89, P=0.04) </plain></SENT>
<SENT sid="7" pm="."><plain>DISCUSSION: We believe that our data may help further composing the molecular mosaic of EGFR-resistant <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>The role of HER-3, IGF-1 and CISH EGFR GCN should be prospectively validated in clinical trials investigating anti-EGFR treatment strategies in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients </plain></SENT>
</text></document>